FoundryBase. Shared educational resources for impactful innovators and

- AARP (2021)

A small study has found that the experimental drug donanemab may slow cognitive decline in Alzheimer's patients. It joins others that show promise.

saved by: FoundryBase
updated about 2 months ago

Visibility: Public (all visitors)

0 likes

View All Articles

No comments yet. Be the first to comment!

Related Chunks

Related chunks with this resource

This Article can be found in 1 chunk

Battling Alzheimer’s

research and new advances in the battle against Alzheimer’s